KOREA WHO
-
-
-
CEO of Kolon TissueGene
Noh Moon-jong
Invossa, a Career-Long Project: Overcoming Domestic Setback to Seek U.S. Revival
-
Last Updated on Apr 29, 2025
-
CEO of Kolon TissueGene
Life Summary
Noh Moon-jong is the CEO of Kolon TissueGene.
He faces the challenge of successfully leading the U.S. clinical trials and product approval of TG-C, a cell and gene therapy for osteoarthritis, which is the company’s only pipeline candidate.
He was born on March 12, 1968.
He graduated from Seoul National University with a degree in Microbiology. He earned both his master’s and doctoral degrees in Molecular Biology from KAIST (Korea Advanced Institute of Science and Technology).
He joined Kolon Central Research Institute, where he worked as a senior researcher and head of the Biotechnology Research Lab. He was dispatched to Kolon TissueGene and participated in the research and development of TG-C (U.S. development name for Invossa), a treatment for knee osteoarthritis. He served as Vice President overseeing R&D and as Chief Technology Officer (CTO) of Kolon TissueGene.
In 2019, he was appointed CEO of Kolon TissueGene.
He is leading the clinical trials of TG-C. He is the only remaining researcher from the early development team of Invossa at TissueGene.
He has a deep attachment to the TG-C development project.
#NohMoonjong #KolonTissueGene #TGCTherapy #Invossa #OsteoarthritisTreatment #ClinicalTrials #BiotechLeadership #KAIST #SNU #Genetherapy
He faces the challenge of successfully leading the U.S. clinical trials and product approval of TG-C, a cell and gene therapy for osteoarthritis, which is the company’s only pipeline candidate.
He was born on March 12, 1968.
He graduated from Seoul National University with a degree in Microbiology. He earned both his master’s and doctoral degrees in Molecular Biology from KAIST (Korea Advanced Institute of Science and Technology).
He joined Kolon Central Research Institute, where he worked as a senior researcher and head of the Biotechnology Research Lab. He was dispatched to Kolon TissueGene and participated in the research and development of TG-C (U.S. development name for Invossa), a treatment for knee osteoarthritis. He served as Vice President overseeing R&D and as Chief Technology Officer (CTO) of Kolon TissueGene.
In 2019, he was appointed CEO of Kolon TissueGene.
He is leading the clinical trials of TG-C. He is the only remaining researcher from the early development team of Invossa at TissueGene.
He has a deep attachment to the TG-C development project.
#NohMoonjong #KolonTissueGene #TGCTherapy #Invossa #OsteoarthritisTreatment #ClinicalTrials #BiotechLeadership #KAIST #SNU #Genetherapy